SAVE THE DATES

28TH EORTC-NCI-AACR SYMPOSIUM ON ‘MOLECULAR TARGETS AND CANCER THERAPEUTICS’

KEY DATES

**28th EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>28th EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’</td>
<td>29 November - 2 December 2016</td>
</tr>
</tbody>
</table>

**Abstract Submission**

- General Abstract Submission Opens: 20 April 2016
- General Abstract Submission Closes: 22 June 2016
- Late Breaking Abstract Submission Opens: 28 September 2016
- Late Breaking Abstract Submission Closes: 12 October 2016

**Registration**

- Early Rate Registration Closes: 16 June 2016
- Regular Rate Registration Closes: 26 October 2016
- Late Registration Closes: 27 November 2016
- Onsite Registration Opens: 28 November 2016

SYMPOSIUM COMMITTEES

**ORGANISING COMMITTEE**

**EORTC**

- J.C. Soria
  - Scientific Chair (France)
- R. Stupp
  - President EORTC (Switzerland)

**NCI**

- L. Helman
  - Scientific Co-chair (USA)
- J. Doroshow
  - Director, Division of Cancer Treatment and Diagnosis, NCI (USA)

**AACR**

- L.A. Garraway
  - Scientific Co-chair (USA)
- J. Baselga
  - President AACR (USA)

**EXECUTIVE COMMITTEE**

- J.C. Soria (France)
- L.J. Helman (USA)
- L.A. Garraway (USA)
- E. Calvo (Spain)
- K. Dhingra (USA)
- V. Golfinopoulos (Belgium)
- R. Plummer (United Kingdom)
- C. Swanton (United Kingdom)

**SCIENTIFIC COMMITTEE**

**EORTC**

- U. Banerji (United Kingdom)
- J.P. Bizzari (USA)
- C. Blank (Netherlands)
- S. Depil (France)
- P. Ho (USA)
- I.D. Horak (Denmark)
- M. Koehler (USA)
- A. Marabelle (France)
- C. Massard (France)
- R. Salazar (Spain)
- M. Verheij (Netherlands)

**NCI**

- J. Abrams (USA)
- J. Collins (USA)
- B. Conley (USA)
- W. Dahut (USA)
- J.L. Gulley (USA)
- T. Hecht (USA)
- L.J. Helman (USA)
- S.P. Ivy (USA)
- P.M. Jacobs (USA)
- P.S. Meltzer (USA)
- R.E. Parchment (USA)
- Y. Pommier (USA)
- P.S. Steeg (USA)
- B. Teicher (USA)
- J.A. Zwiebel (USA)

**AACR**

- C. Abate-Shen (USA)
- C.L. Arteaga (USA)
- J.C. Byrd (USA)
- K.M. Cichowski (USA)
- L. Friedman (USA)
- L.A. Garraway (USA)
- J.C. Chang (USA)
- P. LoRusso (USA)
- F. Michor (USA)
- G.B. Mills (USA)
- A. Ribas (USA)
- V.M. Richon (USA)
- G. Shapiro (USA)
- D. Solit (USA)
- J.A. Sosman (USA)
- A. Yver (USA)
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>WELCOME LETTER</td>
<td>5</td>
</tr>
<tr>
<td>PROGRAMME AT A GLANCE</td>
<td>6</td>
</tr>
<tr>
<td>DETAILED ADVANCE PROGRAMME</td>
<td>8</td>
</tr>
<tr>
<td>29 November 2016</td>
<td>8</td>
</tr>
<tr>
<td>30 November 2016</td>
<td>9</td>
</tr>
<tr>
<td>1 December 2016</td>
<td>10</td>
</tr>
<tr>
<td>2 December 2016</td>
<td>11</td>
</tr>
<tr>
<td>CALL FOR ABSTRACTS</td>
<td>12</td>
</tr>
<tr>
<td>TRAVEL GRANTS</td>
<td>12</td>
</tr>
<tr>
<td>REGISTRATION FEES</td>
<td>13</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>14</td>
</tr>
</tbody>
</table>

## SYMPOSIUM VENUE

ICM – Internationales Congress Center München  
Messegelände  
81823 Munich  
Phone: +49 89 949-20720  
Fax: +49 89 949-20729  
E-mail: info@messe-muenchen.de  
Website: www.icm-muenchen.de

## COMMERCIAL INFORMATION AND SYMPOSIUM SECRETARIAT

c/o ECCO - the European CanCer Organisation  
Avenue E. Mounier 83  
BE-1200 Brussels  
Belgium  
Tel: +32 2 775 0201  
Email: ena2016@ecco-org.eu  
Website: www.ecco-org.eu/ENA2016

## ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)

An application for accreditation has been submitted to the European Accreditation Council for CME (EACCME) of the European Union of Medical Specialists (UEMS).
“bringing clinicians and scientists together to share knowledge and best practice”

“the real bench to bedside approach”
WELCOME LETTER

Dear Colleagues,

It is our great pleasure to announce that the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will take place in Munich, Germany from 29 November to 2 December, 2016.

Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2016 Symposium will bring together academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.

Building on the success and focus of previous highly acclaimed symposiums, this drug development and translational research meeting, focussing on preclinical and phase I studies, will enable delegates to have in-depth scientific discussions on the latest developments in targets and drugs. New data will be revealed, presentation of new drugs that will potentially change daily practice, and numerous opportunities for learning and networking will also be available. The event will also focus on experimental models for cancer detection, diagnosis and treatment. Other major fields covered will include biomarker analysis for prediction and prognosis response; formulation of new drugs; immunotherapy and immunology, signal transduction and inhibition and molecular and cell biology.

EORTC-NCI-AACR 2016 is the platform that brings clinicians and scientists together to share knowledge and best practice, encompassing the real bench to bedside approach. This Symposium creates a unique opportunity to meet and network with fellow academics and scientists in the field of drug discovery and targets in cancer.

The 2016 meeting provides greater opportunities for investigators to present original phase I data due to an increased number of oral slots during plenary sessions, and once again an application has been made to the EACCME® for CME accreditation of this event.

During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer. Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development and the execution of large, prospective, randomised, multicentre cancer clinical trials. This requires a collaborative, global approach, and early and optimal exchange of information. For these reasons, the Symposium has been organised to ensure the maximum amount of interaction and discussion through an exciting range of plenary sessions and lively workshops.

We hope that you will join this unique forum in Munich, and we remain confident that you will make the most of this opportunity to strengthen your connections in the world of drug development, target selection and the impact of new discoveries in molecular biology.

Jean Charles Soria  
Scientific Chair

Roger Stupp  
EORTC President
# Programme at a Glance

For titles of presentations and the latest updates for each session, please bookmark: [www.ecco-org.eu/ENA2016](http://www.ecco-org.eu/ENA2016)

## Tuesday 29 November 2016

**Room 14**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Clinical trial methodology workshop</td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch Break 12.00-13.00</td>
</tr>
<tr>
<td>13:00</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>13:05</td>
<td>Michel Clavel Lecture: New Frontiers in Molecular Guided Therapy</td>
</tr>
<tr>
<td>13:50</td>
<td>Keynote Lecture: Tumour Microenvironment and Its Role in Drug Development</td>
</tr>
<tr>
<td>14:35</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:05</td>
<td>Plenary Session 1: Degrons: Degradation Based Therapeutics</td>
</tr>
<tr>
<td>16:35</td>
<td>Welcome Reception (Exhibition Hall)</td>
</tr>
<tr>
<td>18:30</td>
<td>Poster Viewing (Exhibition Hall)</td>
</tr>
</tbody>
</table>

**Room 13**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Workshop 1: Macrophage-Targeted Immunotherapeutic Agents</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>Workshop 2: Molecular Imaging</td>
</tr>
<tr>
<td>11:00</td>
<td>Workshop 3: Why Antibody Drug Conjugates (ADC) Do Not Work</td>
</tr>
<tr>
<td>12:30</td>
<td>Workshop 4: Pharmacokinetics-Pharmacodynamics of Oncology Agents</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch Break 12.30-14.30</td>
</tr>
<tr>
<td>13:00</td>
<td>Poster in the Spotlight 13.00-13.30 (Exhibition Hall)</td>
</tr>
<tr>
<td>14:30</td>
<td>Regulatory Session</td>
</tr>
<tr>
<td>15:30</td>
<td>Plenary Session 2: Proffered Papers</td>
</tr>
<tr>
<td>16:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17:00</td>
<td>Plenary Session 3: Exploiting Genomic Instability as a Target</td>
</tr>
</tbody>
</table>

## Wednesday 30 November 2016

**Room 14**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Workshop 1: Macrophage-Targeted Immunotherapeutic Agents</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>Workshop 3: Why Antibody Drug Conjugates (ADC) Do Not Work</td>
</tr>
<tr>
<td>12:30</td>
<td>Workshop 4: Pharmacokinetics-Pharmacodynamics of Oncology Agents</td>
</tr>
<tr>
<td>13:00</td>
<td>Poster Viewing (Exhibition Hall)</td>
</tr>
<tr>
<td>14:30</td>
<td>Regulatory Session</td>
</tr>
<tr>
<td>15:30</td>
<td>Plenary Session 2: Proffered Papers</td>
</tr>
<tr>
<td>16:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17:00</td>
<td>Plenary Session 3: Exploiting Genomic Instability as a Target</td>
</tr>
</tbody>
</table>

**Room 13**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15</td>
<td>Exhibition 10:15 - 17:00</td>
</tr>
<tr>
<td>11:00</td>
<td>Poster Viewing (Exhibition Hall)</td>
</tr>
<tr>
<td>13:00</td>
<td>Poster in the Spotlight 13.00-13.30 (Exhibition Hall)</td>
</tr>
<tr>
<td>14:30</td>
<td>Welcome Reception (Exhibition Hall)</td>
</tr>
<tr>
<td>15:30</td>
<td>Poster Viewing (Exhibition Hall)</td>
</tr>
<tr>
<td>18:30</td>
<td>Exhibition 18:30 - 21:00</td>
</tr>
<tr>
<td>Time</td>
<td>Thursday 1 December 2016</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>9:00</td>
<td>Plenary Session 4</td>
</tr>
<tr>
<td></td>
<td>New Horizons for Epigenetic Modulators</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>Plenary session 5</td>
</tr>
<tr>
<td></td>
<td>Liquid biopsy - Practical Applications in the Clinic</td>
</tr>
<tr>
<td>12:30</td>
<td>Poster Viewing (Exhibition Hall)</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch Break 12:30-14:30</td>
</tr>
<tr>
<td>13:00</td>
<td>Poster in the Spotlight 13:00-13:30 (Exhibition Hall)</td>
</tr>
<tr>
<td>14:30</td>
<td>Regulatory Session</td>
</tr>
<tr>
<td>15:30</td>
<td>Plenary Session 6</td>
</tr>
<tr>
<td></td>
<td>Proffered Papers</td>
</tr>
<tr>
<td>16:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17:00</td>
<td>Plenary Session 7</td>
</tr>
<tr>
<td></td>
<td>Cellular Therapy</td>
</tr>
<tr>
<td>18:30</td>
<td></td>
</tr>
</tbody>
</table>

*Exhibition 10:15 - 17:00*
29 November 2016

Workshop: Clinical Trial Methodology
10:00 - 12:00
Chair: V. Golfinopoulos (Belgium)
Chair: L.J. Helman (USA)
10:00  N of one to pragmatically designed phase II trials
Speaker: D. Renouf (Canada)
10:20  New designs in early drug development
Speaker: E. Calvo (Spain)
10:40  Pragmatic phase III trials
Speaker: M. Koehler (USA)
11:00  Sequencing in Basket rare disease trials
Speaker: J. Khan (USA)
11:20  Round Table Discussion

FDA
Panel: A. McKee (USA)

EMA
Panel: To be announced

Industry
Panel: A. Yver (USA)

Industry
Panel: To be announced

Academic
Panel: J.Y. Blay (France)

Michel Clavel Lecture: New Frontiers in Molecular Guided Therapy
13:05 - 13:50
Chair: J.C. Soria (France)
13:05  Keynote Lecturer: J.S. De Bono (United Kingdom)

Keynote Lecture: Tumour Microenvironment and Its Role in Drug Development
13:50 - 14:35
Chair: L.A. Garraway (USA)
13:50  Keynote Lecturer: M.J. Bissell (USA)

Plenary Session 1: Degrons: Degradation Based Therapeutics
15:05 - 16:35
Chair: To be announced
Chair: C. Crews (USA)
15:05  Peptidic degrons in biology and disease
Speaker: To be announced
15:25  The use of small molecules to regulate intracellular protein levels
Speaker: C. Crews (USA)
15:45  Structural and biochemical approaches to modifying protein degradation
Speaker: A. Ciulli (United Kingdom)
16:05  Discussion and Oral Abstract(s)

Opening Ceremony
13:00 - 13:05
Welcome to the 28th EORTC-NCI-AACR symposium
Chair: J.C. Soria (France)
ENA 2016 SCIENTIFIC PROGRAMME

30 NOVEMBER 2016

Workshop 1: Macrophage-Targeted Immunotherapeutic Agents
09:00 - 10:30
Chair: J. Tabernero (Spain)
Chair: A. Tolcher (USA)

09:00  cFMS targeted therapeutics
Speaker: To be announced

09:20  Please Eat Me – Targeting CD47
Speaker: C. Takimoto (USA)

09:40  Novel macrophage checkpoint activators
Speaker: D. Law (USA)

10:00 Discussion

Workshop 2: Molecular Imaging
09:00 - 10:30
Chair: E. Calvo (Spain)
Chair: K. Dhingra (USA)

09:00  PSMA based theranostics
Speaker: H.R. Kulkarni (Germany)

09:20  Quantitative Radiomics in oncology
Speaker: R. Gillies (USA)

09:40  Imaging based heterogeneity vs genomic heterogeneity
Speaker: N. Birkbak (United Kingdom)

10:00 Discussion

Workshop 3: Why Antibody Drug Conjugates (ADC) Do Not Work
11:00 - 12:30
Chair: To be announced
Chair: S. Depil (France)

11:00  Why have so few ADCs succeeded in the clinic? Lessons learnt from 20 years of ADC targeting
Speaker: M. Sliwkowski (USA)

11:20  Next generation ADC targets, payloads, and linkers
Speaker: To be announced

11:40  Anetumab Ravtansine, a promising ADC for solid tumours
Speaker: R. Hassan (USA)

12:00  Peptide drug conjugates
Speaker: R. Wooster (USA)

12:20 Discussion

Workshop 4: Pharmacokinetics-Pharmacodynamics of Oncology Agents
11:00 - 12:30
Chair: M. Koehler (USA)
Chair: R. Plummer (United Kingdom)

11:00  Therapeutic drug monitoring for drug biologics
Speaker: E. Calvo (Spain)

11:20  PK/PD in the era of immunooncology
Speaker: D. De Alwis (USA)

11:40  Regulatory view on importance of PK/PD in drugs with breakthrough activity
Speaker: Y. Wang (USA)

12:00 Discussion

Regulatory Session: To be announced
14:30 - 15:30
## Plenary Session 2: Proffered Paper Session
**15:30 - 16:30**
Late Breaking and Oral presentations

## Plenary Session 3: Exploiting Genomic Instability as a Target
**17:00 - 18:30**
Chair: C. Swanton (United Kingdom)  
Chair: J.C. Soria (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00</td>
<td>Replication stress and cancer</td>
<td>A. Aguilera (Spain)</td>
</tr>
<tr>
<td>17:15</td>
<td>New targets</td>
<td>T. Helleday (Sweden)</td>
</tr>
<tr>
<td>17:30</td>
<td>Insights into somatic copy number changes in cancer</td>
<td>J. Whetstine (USA)</td>
</tr>
<tr>
<td>17:45</td>
<td>APOBEC mutagenesis</td>
<td>S. Nik-Zainal (United Kingdom)</td>
</tr>
</tbody>
</table>

Discussion and Oral Abstract(s)

## 1 DECEMBER 2016

### Plenary Session 4: New Horizons for Epigenetic Modulators
**09:00 - 10:30**
Chair: B. Brown (United Kingdom)  
Chair: M. Dawson (Australia)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Synthetic lethality with epigenetic modulators</td>
<td>R. Copeland (USA)</td>
</tr>
<tr>
<td>09:15</td>
<td>New molecular alterations in epigenetic pathways</td>
<td>M. Dawson (Australia)</td>
</tr>
<tr>
<td>09:30</td>
<td>Epigenetic modulators as new immunoncology therapies</td>
<td>S. Postal-Vinay (France)</td>
</tr>
<tr>
<td>09:45</td>
<td>Role of arginine methyltransferase as cancer targets</td>
<td>L.A. Garraway (USA)</td>
</tr>
</tbody>
</table>

Discussion and Oral Abstract(s)

### Plenary Session 5: Liquid Biopsy - Practical Applications in the Clinic
**11:00 - 12:30**
Chair: F. André (France)  
Chair: K. Dhingra (USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>RNA based actionable biomarkers</td>
<td>M. Noerholm (Germany)</td>
</tr>
<tr>
<td>11:15</td>
<td>ctDNA for molecular stratification - Ready for primetime?</td>
<td>N. Rosenfeld (United Kingdom)</td>
</tr>
<tr>
<td>11:30</td>
<td>Implementing liquid biopsy in pivotal clinical trial - Lessons learnt</td>
<td>K. Lindert (USA)</td>
</tr>
<tr>
<td>11:45</td>
<td>Advances in proteomics analysis in liquid biopsies</td>
<td>To be announced</td>
</tr>
</tbody>
</table>

Discussion and Oral Abstract(s)
Regulatory Session: To be announced
14:30 - 15:30

Plenary Session 6: Proffered Paper Session
15:30 - 16:30
Late Breaking and Oral presentations

Plenary Session 7: Cellular Therapy
17:00 - 18:30
Chair: To be announced
Chair: R. Amado (USA)
17:00 Cellular engineering
   Speaker: To be announced
17:15 CAR T cells
   Speaker: To be announced
17:30 The development of receptor–engineered T-cells
   Speaker: T. Holdich (United Kingdom)
17:45 Overcoming the non-T cell inflamed micro-environment
   Speaker: M. Pule (United Kingdom)

Discussion and Oral Abstract(s)

2 DECEMBER 2016

Plenary Session 8: Exceptional Response and Expected Resistance
09:00 - 10:30
Chair: D. Solit (USA)
Chair: L.A. Garraway (USA)
09:00 What do we learn from exceptional responders
   Speaker: F. André (France)
09:15 Co-variants role in response and resistance
   Speaker: L.A. Garraway (USA)
09:30 Predictive mutations in combination with ER expression
   Speaker: C.L. Arteaga (USA)
09:45 PI3K pathway
   Speaker: D. Solit (USA)
10:00 DNA damage repair mutations
   Speaker: G.B. Mills (USA)
10:15 Discussion and Oral Abstract(s)

Plenary Session 9: Combination of Immunecheckpoint Blockers with Other Standard Anti-Cancer Therapies
11:00 - 13:00
Chair: R. Plummer (United Kingdom)
Chair: E. Calvo (Spain)
11:00 Immunecheckpoint Blockers and chemotherapy
   Speaker: To be announced
11:15 Immunecheckpoint Blockers and radiation therapy
   Speaker: E. Deutsch (France)
11:30 Immunecheckpoint Blockers and kinase inhibitors
   Speaker: A. Ribas (USA)
11:45 Immunecheckpoint Blockers and oncolytic virus
   Speaker: K. Harrington (United Kingdom)

Discussion and Oral Abstract(s)
CALL FOR ABSTRACTS

Abstract submission opens 20 April 2016
Abstract submission closes 22 June 2016
Abstracts can only be submitted online at www.ecco-org.eu/ENA2016
Late-breaking abstract submission opens 28 September 2016
Late-breaking abstract submission closes 12 October 2016

For more information on abstract topics, format, submission and selection process, please visit the Symposium website: www.ecco-org.eu/ENA2016

TRAVEL GRANTS

Travel grant submission opens 20 April 2016
Travel grant submission closes 24 June 2016
Travel grants can be submitted online www.ecco-org.eu/ENA2016

For more information on travel grants please visit the Symposium website: www.ecco-org.eu/ENA2016
# Registration Fees

Register early and benefit from significant savings on fees. Pre-registration and corresponding payment must be received by the deadlines indicated.

## Early Rate Deadline: 16 June 2016

<table>
<thead>
<tr>
<th>Category</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Rate Industry</td>
<td>EUR 775</td>
</tr>
<tr>
<td>Early Rate Academics / Institutional</td>
<td>EUR 450</td>
</tr>
<tr>
<td>Early Rate Students / Residents in training*</td>
<td>EUR 250</td>
</tr>
</tbody>
</table>

## Regular Rate Deadline: 26 October 2016

<table>
<thead>
<tr>
<th>Category</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Rate Industry</td>
<td>EUR 995</td>
</tr>
<tr>
<td>Regular Rate Academics / Institutional</td>
<td>EUR 675</td>
</tr>
<tr>
<td>Regular Rate Students / Residents in training*</td>
<td>EUR 300</td>
</tr>
</tbody>
</table>

## Late Rate Deadline: 27 November 2016

<table>
<thead>
<tr>
<th>Category</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Late Rate Industry</td>
<td>EUR 1,200</td>
</tr>
<tr>
<td>Late Rate Academics / Institutional</td>
<td>EUR 775</td>
</tr>
<tr>
<td>Late Rate Students / Residents in training*</td>
<td>EUR 350</td>
</tr>
</tbody>
</table>

## Onsite Rate As of 28 November 2016

<table>
<thead>
<tr>
<th>Category</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onsite Rate Industry</td>
<td>EUR 1,300</td>
</tr>
<tr>
<td>Onsite Rate Academics / Institutional</td>
<td>EUR 1,150</td>
</tr>
<tr>
<td>Onsite Rate Students / Residents in training*</td>
<td>EUR 350</td>
</tr>
<tr>
<td>Day rate (available only onsite)</td>
<td>EUR 400</td>
</tr>
</tbody>
</table>

* A letter from the Head of Department confirming the student/resident in training status is required. This letter should be uploaded online at the time of registration.
GENERAL INFORMATION

CATERING
Coffee breaks courtesy of the organiser are scheduled during the Symposium. Lunch will not be provided. A variety of outlets will be open for the sale of refreshments at lunchtime and throughout the day.

HOTEL ACCOMMODATION
All hotel bookings, as well as additional services like airport transfers, restaurants or half and full day excursions can be booked through our local partner Weichlein Tours + Incentives, which is a ground service specialist based in Munich with a vast experience in hotel bookings, conferences & congresses and incentive group operations. The online booking system is published at www.ecco-org.eu/ENA2016. You will be able to benefit from specially negotiated congress rates and a wide range of different hotel categories. Once you book, Weichlein Tours + Incentives will send you a confirmation of your services.

For any further questions please contact ena2016@weichlein.de or +49 (0) 89 856 366 30 - the team at Weichlein Tours + Incentives will be happy to assist you. Accommodation deadline: 16 August 2016.

EXHIBITION
The EORTC-NCI-AACR 2016 exhibition represents an essential part of the Symposium, providing participants with an excellent platform for networking as well as the perfect opportunity to gain critical insight into the latest solutions and services in drug discovery and targets in cancer.

The EORTC-NCI-AACR 2016 Invitation to Industry (ITI) offers companies a wide and exciting range of opportunities and tools to achieve the highest level of exposure to Symposium delegates. Download the Invitation to Industry brochure, see the exhibition floor plan and the list of exhibitors here: www.ecco-org.eu/ENAExhibition

INSURANCE
The organisers do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements regarding health and travel insurance.

LANGUAGE AND TRANSLATION
The official language of the Symposium is English. No simultaneous translations will be provided.

PASSPORT AND VISA
A valid passport is required for entry into Germany. A visa may be required for some countries. For information about visa and passports, please contact your local German Embassy at least 3 months prior to your departure to join us in Munich.

TRAVEL
Delegates benefit from free travel within the inner district MVV network of Munich, on presentation of the delegate pass.

WELCOME RECEPTION
29 November 2016, 16:35 – 18:30
All registered delegates are invited to join us for the Welcome Reception. The reception will take place in the exhibition area of the Congress Centre. Come and network with your friends and colleagues in a relaxed setting.